Inhibition of NFE2L2 by trigonelline reverses resistance to GPX4 inhibitor-induced ferroptosis in head and neck cancer cells[110], implicating NFE2L2 in the development of resistance to GPX4 inhibitors. Here, NFE2L2 is linked to head and neck cancer.